Update from Services Australia
Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented 1 September 2020 that may be of interest for your members. This information relates to the administration of these listings by Services Australia (the Agency). For further information on broader PBS changes, please visit PBS website.
Prescribers can now request authority approval for more PBS listings via the Online PBS Authorities system which provides real time assessment result (approved or rejected).
Pembrolizumab for Primary mediastinal B-cell lymphoma (PMBCL):
As of 1 September 2020, pembrolizumab has been PBS listed for treatment of primary mediastinal B-cell lymphoma. It is Authority Required (in writing) for initial and grandfather treatment and Authority Required (telephone/electronic) for continuing treatment. You can submit your written authority requests for this item for treatment of PMBCL through the Health Professional Online Services ( HPOS
) secure form upload facility which removes the need to post authority requests to the Agency. Continuing authority requests can be submitted via the Online PBS Authorities system.
Further information on how to apply for authority approval for pembrolizumab for this condition on the Services Australia Website.
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL):
Acalabrutinib has now been listed for CLL and SLL as Authority Required (Telephone/Electronic). Authority requests can be submitted via the Online PBS Authorities system.
Methlyphenidate for Attention Deficit Hyperactivity Disorder (ADHD):
A new strength, 60mg modified release capsule, has been listed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as Authority Required (Telephone/Electronic).
Additional PBS listings available through the Online PBS Authorities system:
- Continuing authority requests for pembrolizumab and brentuximab for refractory Hodgkin lymphoma
- Continuing authority requests for entrectinib, crizotinib and osimertinib for Stage IIIB or Stage IV NSCLC
- Blinatumomab for acute lymphoblastic leukaemia, consolidation treatment and balance of supply for induction treatment
- Inotuzumab for acute lymphoblastic leukaemia, consolidation treatment
- Ponatinib and dasatinib for acute lymphoblastic leukaemia, continuing treatment
- Azacitidine for Chronic Myelomonocytic Leukaemia, continuing treatment
- Azacitidine for Myelodysplastic syndrome, continuing treatment
- Midostaurin for Acute Myeloid Leukaemia, continuing treatment
- Vorinostat for Cutaneous T-cell lymphoma, continuing treatment
- Lenalidomide for Myelodysplastic syndrome, continuing treatment
To learn more about these updates, please contact Services Australia directly.
At Practice Managers Australia, we support Practice Managers in both staff recruitment and retention and ensure that our service and advice is tailored to your specific goals to promote growth and flourishing.
Contact us on 03 9946 7333 or info@practicemanagersaustralia.com.au and follow our LinkedIn and Facebook pages for more information.
OUR PARTNERS
